WO2016026423A1 - Macrocycles substitués utilisés comme inhibiteurs des kinases et leurs méthodes d'utilisation - Google Patents

Macrocycles substitués utilisés comme inhibiteurs des kinases et leurs méthodes d'utilisation Download PDF

Info

Publication number
WO2016026423A1
WO2016026423A1 PCT/CN2015/087343 CN2015087343W WO2016026423A1 WO 2016026423 A1 WO2016026423 A1 WO 2016026423A1 CN 2015087343 W CN2015087343 W CN 2015087343W WO 2016026423 A1 WO2016026423 A1 WO 2016026423A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
compounds
cancer
pharmaceutically acceptable
kinase
Prior art date
Application number
PCT/CN2015/087343
Other languages
English (en)
Inventor
Xiaoyang Xia
Dawei Zhang
Original Assignee
Teligene Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teligene Ltd filed Critical Teligene Ltd
Priority to JP2017510559A priority Critical patent/JP6609308B2/ja
Priority to EP15833622.2A priority patent/EP3183256A4/fr
Priority to US15/500,927 priority patent/US10159663B2/en
Priority to CN201580043435.7A priority patent/CN107207528B/zh
Publication of WO2016026423A1 publication Critical patent/WO2016026423A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne de nouveaux composés macrocycles substitués, des sels pharmaceutiquement acceptables, des solvates et des hydrates de ceux-ci. Les composés et compositions de l'invention présentent une activité inhibitrice des protéines kinases, et devraient donc s'avérer utiles pour le traitement de maladies et affections induites par les protéines kinases.
PCT/CN2015/087343 2014-08-20 2015-08-18 Macrocycles substitués utilisés comme inhibiteurs des kinases et leurs méthodes d'utilisation WO2016026423A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2017510559A JP6609308B2 (ja) 2014-08-20 2015-08-18 キナーゼ阻害剤としての置換マクロサイクル
EP15833622.2A EP3183256A4 (fr) 2014-08-20 2015-08-18 Macrocycles substitués utilisés comme inhibiteurs des kinases et leurs méthodes d'utilisation
US15/500,927 US10159663B2 (en) 2014-08-20 2015-08-18 Substituted macrocycles useful as kinases inhibitors and methods of use thereof
CN201580043435.7A CN107207528B (zh) 2014-08-20 2015-08-18 作为激酶抑制剂的经取代大环及其使用方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461070250P 2014-08-20 2014-08-20
US61/070,250 2014-08-20

Publications (1)

Publication Number Publication Date
WO2016026423A1 true WO2016026423A1 (fr) 2016-02-25

Family

ID=55350197

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2015/087343 WO2016026423A1 (fr) 2014-08-20 2015-08-18 Macrocycles substitués utilisés comme inhibiteurs des kinases et leurs méthodes d'utilisation

Country Status (1)

Country Link
WO (1) WO2016026423A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018137679A1 (fr) * 2017-01-25 2018-08-02 Teligene Ltd Procédé de préparation de (10r) -7- (2-aminoacétyl) amino-12-fluoro-2, 10, 16-triméthyl-15-oxo-10, 15, 16, 17-tétrahydro-2h-8, 4- (metheno) pyrazolo [4, 3-h] [2, 5, 11] -benzoxadiazacyclotétradécine-3-carbonitrile
CN110950890A (zh) * 2018-09-27 2020-04-03 北京赛林泰医药技术有限公司 取代的咪唑并[4,5-c]喹啉大环化合物作为多靶点激酶抑制剂
CN111201235A (zh) * 2017-10-10 2020-05-26 辉瑞公司 劳拉替尼游离碱水合物的结晶形式
WO2020228747A1 (fr) 2019-05-14 2020-11-19 Teligene Ltd Macrocycles substitués utiles en tant qu'inhibiteurs de kinase
CN115746023A (zh) * 2022-10-27 2023-03-07 复旦大学 一种作为蛋白激酶抑制剂的含吲唑结构的杂环大环化合物及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011138751A2 (fr) * 2010-05-04 2011-11-10 Pfizer Inc. Dérivés hétérocycliques destinés au traitement de maladies
WO2013132376A1 (fr) * 2012-03-06 2013-09-12 Pfizer Inc. Dérivés macrocycliques pour le traitement de maladies prolifératives
WO2014207606A1 (fr) * 2013-06-28 2014-12-31 Pfizer Inc. Formes solides d'un inhibiteur de kinases macrocycliques
WO2015050989A2 (fr) * 2013-10-01 2015-04-09 Cs Therapeutics Inc. Composés macrocycliques destinés au traitement de maladies prolifératives

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011138751A2 (fr) * 2010-05-04 2011-11-10 Pfizer Inc. Dérivés hétérocycliques destinés au traitement de maladies
WO2013132376A1 (fr) * 2012-03-06 2013-09-12 Pfizer Inc. Dérivés macrocycliques pour le traitement de maladies prolifératives
WO2014207606A1 (fr) * 2013-06-28 2014-12-31 Pfizer Inc. Formes solides d'un inhibiteur de kinases macrocycliques
WO2015050989A2 (fr) * 2013-10-01 2015-04-09 Cs Therapeutics Inc. Composés macrocycliques destinés au traitement de maladies prolifératives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP3183256A4 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018137679A1 (fr) * 2017-01-25 2018-08-02 Teligene Ltd Procédé de préparation de (10r) -7- (2-aminoacétyl) amino-12-fluoro-2, 10, 16-triméthyl-15-oxo-10, 15, 16, 17-tétrahydro-2h-8, 4- (metheno) pyrazolo [4, 3-h] [2, 5, 11] -benzoxadiazacyclotétradécine-3-carbonitrile
CN111201235A (zh) * 2017-10-10 2020-05-26 辉瑞公司 劳拉替尼游离碱水合物的结晶形式
CN111201235B (zh) * 2017-10-10 2023-02-10 辉瑞公司 劳拉替尼游离碱水合物的结晶形式
CN110950890A (zh) * 2018-09-27 2020-04-03 北京赛林泰医药技术有限公司 取代的咪唑并[4,5-c]喹啉大环化合物作为多靶点激酶抑制剂
WO2020228747A1 (fr) 2019-05-14 2020-11-19 Teligene Ltd Macrocycles substitués utiles en tant qu'inhibiteurs de kinase
CN112533927A (zh) * 2019-05-14 2021-03-19 苏州韬略生物科技有限公司 可用作激酶抑制剂的被取代的大环
CN115746023A (zh) * 2022-10-27 2023-03-07 复旦大学 一种作为蛋白激酶抑制剂的含吲唑结构的杂环大环化合物及其制备方法

Similar Documents

Publication Publication Date Title
US10159663B2 (en) Substituted macrocycles useful as kinases inhibitors and methods of use thereof
US9694011B2 (en) Substituted pyrazolopyrimidines as kinases inhibitors
EP2833886B1 (fr) Quinoléines substituées en tant qu'inhibiteurs de tyrosine kinase de bruton
WO2016026423A1 (fr) Macrocycles substitués utilisés comme inhibiteurs des kinases et leurs méthodes d'utilisation
EP3102571B1 (fr) Pyrimidines substituées utiles en tant qu'inhibiteurs de kinase d'egfr-t790m
WO2013173254A1 (fr) Composés bicycliques utilisés en tant qu'inhibiteurs des kinases
MX2011004683A (es) Antagonistas de la via hedgehog de ftalazina disustituida.
CN111542522B (zh) 可用作激酶抑制剂的被取代的吡唑并嘧啶
EP3844166B1 (fr) Macrocycles substitués utiles en tant qu'inhibiteurs de kinase
US20140350050A1 (en) Pyridine compounds as inhibitors of kinase
US11427559B2 (en) Substituted quinolines useful as kinase inhibitors
JP2014532063A (ja) キナーゼ阻害剤としてのキナゾリン誘導体およびその使用方法
WO2014110466A1 (fr) Composés pyridine utilisés en tant qu'inhibiteurs de pi3 kinase
WO2014139391A1 (fr) Utilisation de composés de pyridine substituée en tant qu'inhibiteurs de kinases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15833622

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 15500927

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2017510559

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2015833622

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2015833622

Country of ref document: EP